Compare DSM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSM | FDMT |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.5M | 455.4M |
| IPO Year | N/A | 2020 |
| Metric | DSM | FDMT |
|---|---|---|
| Price | $6.18 | $7.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 161.7K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 3.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | N/A | $162.43 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $4.69 | $2.24 |
| 52 Week High | $6.05 | $12.34 |
| Indicator | DSM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 71.67 | 30.51 |
| Support Level | $5.97 | $7.67 |
| Resistance Level | $6.05 | $11.81 |
| Average True Range (ATR) | 0.05 | 0.74 |
| MACD | 0.02 | -0.24 |
| Stochastic Oscillator | 96.15 | 4.06 |
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.